6月9日 - ** 制药公司TG Therapeutics（TGTX.O）的股价在盘前交易中上涨3%，至42美元
** 该公司表示，其多发性硬化症药物Briumvi在治疗重症肌无力（一种导致肌肉无力和疲劳的罕见疾病）的试验中显示，82%的患者日常活动能力有所改善
** 据称，在一项涉及11名患者的早期研究中，平均症状评分改善了4分以上；患者总体耐受性良好
**TGTX表示已启动中期临床试验，测试Briumvi作为维持治疗以持续控制症状
** 称计划招募约120名患者；对现有药物efgartigimod有反应的患者将接受Briumvi或安慰剂治疗
** 补充称，公司旨在将已获批用于治疗多发性硬化症的Briumvi拓展至新适应症
** 截至上一交易日收盘，该公司股价年内累计下跌约19%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.